好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Epilepsy-related and All-cause Healthcare Resource Utilization After Initiation of Adjunctive Cenobamate
Epilepsy/Clinical Neurophysiology (EEG)
P1 - Poster Session 1 (8:00 AM-9:00 AM)
11-002
To evaluate the comparative effect of initiating cenobamate vs selected antiseizure medications (ASMs, brivaracetam, clobazam, eslicarbazepine, lacosamide, or perampanel) on epilepsy-related and all-cause inpatient (IP) and emergency room (ER) utilization rates.
Cenobamate is an ASM approved for adults in the US that has demonstrated efficacy across focal seizure subtypes.
A retrospective observational study using de-identified electronic health records from the Truveta database identified adults (≥18 years) with an epilepsy diagnosis who initiated cenobamate or another selected ASM between 1/1/202012/52024. The other selected ASMs were chosen based on similar patterns of use primarily in medication-resistant epilepsy. Patients were included if they reached a minimum effective dose (100 mg for cenobamate, per US label for selected ASMs) and remained on treatment for ≥90 days after initiation. Patients with an epilepsy-related ER visit or IP admission in the previous 180 days were excluded. The endpoints were the annual rate of epilepsy-related and all-cause ER visits and IP admissions evaluated during the 90-day period after initiation and subsequent 360-day period.
The study sample contained 1805 patients (mean age 41.4 years, 51.2% female), including 361 patients who initiated cenobamate and 1444 propensity-matched patients who initiated other selected ASMs. In the epilepsy-related analysis, treatment with cenobamate was associated with a 48% reduction (95% CI: 29%-61%) vs the selected ASM group in annual IP admissions, and a 35% reduction (95% CI: 8%-54%) in annual ER visits. In the all-cause analysis, treatment with cenobamate was associated with a 37% reduction (95% CI: 25%-48%) vs the select ASM group in annual IP admissions, and a 34% reduction (95% CI: 23%-43%) in annual ER visits.
Initiating cenobamate was associated with a significant reduction in both epilepsy-related and all-cause IP admissions and ER visits compared to propensity-matched patients who similarly could have initiated cenobamate but instead initiated other ASMs.
Authors/Disclosures
Emily Klatte, MD (Ohio Health Neurological Physicians)
PRESENTER 		Dr. Klatte has received personal compensation in the range of $0-$499 for serving as a Consultant for SK Life Science . Dr. Klatte has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis, Inc. Dr. Klatte has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis.
Sean Stern (SK life science) Mr. Stern has received personal compensation for serving as an employee of SK Life Science.
Marc Kamin, MD Dr. Kamin has received personal compensation for serving as an employee of SK LIFE SCIENCE INC.
Clarence Wade (SK life science) Clarence Wade has nothing to disclose.
Wesley Kerr, MD, PhD (University of Pittsburgh) Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Lifesciences. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Kerr has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for QurAlis. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. The institution of Dr. Kerr has received research support from NINDS. The institution of Dr. Kerr has received research support from American Epilepsy Society. The institution of Dr. Kerr has received research support from 好色先生. The institution of Dr. Kerr has received research support from SK Life Science. The institution of Dr. Kerr has received research support from Biohaven Pharmaceuticals. Dr. Kerr has received publishing royalties from a publication relating to health care.